Skip to main content

Table 2 Baseline characteristics and disease history

From: Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial

Characteristic

Placebo

OROS MPH

OROS MPH

 

(n =97)

54 mg (n= 87)

72 mg (n =92)

Age, years

   

 Mean ± SD

35.5 ± 8.8

35.5 ± 11.8

35.8 ± 10.1

 Median (range)

36 (18-57)

33 (18-64)

35 (18-60)

Sex, n (%)

   

 Female

45 (46.4)

44 (50.6)

42 (45.7)

 Male

52 (53.6)

43 (49.4)

50 (54.3)

Educational status, n (%)

   

 Primary school

7 (7.2)

8 (9.2)

8 (8.7)

 Secondary  school

40 (41.2)

24 (27.6)

29 (31.5)

 High school

29 (29.9)

29 (33.3)

26 (28.3)

 University

21 (21.6)

26 (29.9)

29 (31.5)

Age at ADHD diagnosis, years (mean ± SD)

31.9 ± 12.8

31.2 ± 15.1

32.4 ± 13.0

Adult ADHD type, n (%)

   

 Combined

73 (75.3)

59 (67.8)

62 (67.4)

 Predominantly  inattentive

23 (23.7)

26 (29.9)

28 (30.4)

 Predominantly  hyperactive– impulsive

1 (1.0)

2 (2.3)

2 (2.2)

Family history of ADHD, n (%)

53 (54.6)

55 (63.2)

52 (56.5)

History of mood and anxiety disorder, n (%)

50 (51.5)

39 (44.8)

39 (42.4)

Baseline CAARS-O:SV (mean ± SD)

36.5 ± 6.1

35.7 ± 6.8

37.3 ± 6.4